2N PHARMA
Large company
2N PHARMA
Description
Through innovative science, compassion, and a relentless commitment to progress, we aim to transform the lives of those affected by ALS. We are developing Mitometin, a small molecule drug, to be a truly disease-modifying therapeutic. We are driven by our profound desire to make a genuine difference for people living with this unforgiving brain disease and strongly believe that our work to develop new medicine to treat ALS will yield insights applicable to other neurological disorders.
2N PHARMA
Address
Novi Science Park, Niels Jernes Vej 10
9220 Aalborg Ø, Denmark
9220 Aalborg Ø, Denmark
Contact
info@2npharma.com
Description
Through innovative science, compassion, and a relentless commitment to progress, we aim to transform the lives of those affected by ALS. We are developing Mitometin, a small molecule drug, to be a truly disease-modifying therapeutic. We are driven by our profound desire to make a genuine difference for people living with this unforgiving brain disease and strongly believe that our work to develop new medicine to treat ALS will yield insights applicable to other neurological disorders.
Matchmaking
Connect with 2N PHARMA
This entity is yours?
Update informationPosition on the value chain
With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.
Bio-resources and biobanking
- Cells, tissues and humanized xeno-organs
- Biosamples
- Viral, phage or bacterial specimen
Identification of biotherapies
- Target identification
- Target validation
- Screening
Drug design
- Drug assessment
- Drug engineering
- In vitro preclinical studies
Clinical validation
- Clinical trials
- In vivo preclinical validation
- Pre-industrial scale production
Production
- Upstream processes
- Downstream processes
- Quality control
Market access
- CE mark / market authorisation
- Payment / Reimbursement
- Care pathways